These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 10735781)

  • 21. In vitro effect of hemodilution on activated clotting time and high-dose thrombin time during cardiopulmonary bypass.
    Huyzen RJ; van Oeveren W; Wei F; Stellingwerf P; Boonstra PW; Gu YJ
    Ann Thorac Surg; 1996 Aug; 62(2):533-7. PubMed ID: 8694618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heparin pretreatment does not alter heparin requirements during cardiopulmonary bypass.
    Nicholson SC; Keeling DM; Sinclair ME; Evans RD
    Br J Anaesth; 2001 Dec; 87(6):844-7. PubMed ID: 11878684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin?
    Dietrich W
    J Cardiovasc Pharmacol; 1996; 27 Suppl 1():S50-7. PubMed ID: 8938284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.
    Mochizuki T; Olson PJ; Szlam F; Ramsay JG; Levy JH
    Anesth Analg; 1998 Oct; 87(4):781-5. PubMed ID: 9768770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery.
    Despotis GJ; Hogue CW; Saleem R; Bigham M; Skubas N; Apostolidou I; Qayum A; Joist JH
    Anesth Analg; 2001 Jul; 93(1):28-32. PubMed ID: 11429333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measurement of thrombin generation intra-operatively and its association with bleeding tendency after cardiac surgery.
    Bosch YP; Al Dieri R; ten Cate H; Nelemans PJ; Bloemen S; de Laat B; Hemker C; Weerwind PW; Maessen JG; Mochtar B
    Thromb Res; 2014 Mar; 133(3):488-94. PubMed ID: 24388571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer.
    Young JA; Kisker CT; Doty DB
    Ann Thorac Surg; 1978 Sep; 26(3):231-40. PubMed ID: 110273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inflammo-coagulatory response, extrinsic pathway thrombin generation and a new theory of activated clotting time interpretation.
    Gil W
    Perfusion; 2001 Jan; 16(1):27-35. PubMed ID: 11192304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prolonged Activated Clotting Time after Protamine Administration Does Not Indicate Residual Heparinization after Cardiopulmonary Bypass in Pediatric Open Heart Surgery.
    Yamamoto T; Wolf HG; Sinzobahamvya N; Asfour B; Hraska V; Schindler E
    Thorac Cardiovasc Surg; 2015 Aug; 63(5):397-403. PubMed ID: 26121380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: Impact of low antithrombin activity.
    Manlhiot C; Gruenwald CE; Holtby HM; Brandão LR; Chan AK; Van Arsdell GS; McCrindle BW
    J Thorac Cardiovasc Surg; 2016 Feb; 151(2):444-50. PubMed ID: 26553458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Titrated versus conventional anticoagulation management for thrombin generation in cardiac surgery: a randomized controlled trial.
    Li H; Bartoszko J; Serrick C; Rao V; Karkouti K
    Can J Anaesth; 2022 Sep; 69(9):1117-1128. PubMed ID: 35799088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass.
    Ovrum E; Brosstad F; Am Holen E; Tangen G; Abdelnoor M
    Circulation; 1995 Nov; 92(9):2579-84. PubMed ID: 7586360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The activated coagulation time: suitability for monitoring heparin effect and neutralization during pediatric cardiac surgery.
    Martindale SJ; Shayevitz JR; D'Errico C
    J Cardiothorac Vasc Anesth; 1996 Jun; 10(4):458-63. PubMed ID: 8776637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Point-of-Care Measurement of Kaolin Activated Clotting Time during Cardiopulmonary Bypass: A Single Sample Comparison between ACT Plus and i-STAT.
    Vranken NPA; Theelen AJAJ; Orbons T; Barenbrug PJC; Weerwind PW
    J Extra Corpor Technol; 2021 Mar; 53(1):57-61. PubMed ID: 33814607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A change in anticoagulation monitoring improves safety, reduces transfusion, and reduces costs in infants on cardiopulmonary bypass.
    Machovec KA; Jooste EH; Walczak RJ; Homi HM; Jaquiss RD; Lodge AJ; Ames WA
    Paediatr Anaesth; 2015 Jun; 25(6):580-6. PubMed ID: 25530420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of a thrombin inhibitor peptide as an alternative to heparin in cardiopulmonary bypass surgery.
    Chomiak PN; Walenga JM; Koza MJ; Reilly TM; Turlapathy P; Pifarre R
    Circulation; 1993 Nov; 88(5 Pt 2):II407-12. PubMed ID: 7993389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monitoring thrombin generation with prothrombin fragment 1.2 assay during cardiopulmonary bypass surgery.
    Knudsen L; Hasenkam JM; Kure HH; Hughes P; Bellaiche L; Ahlburg P; Djurhuus C
    Thromb Res; 1996 Oct; 84(1):45-54. PubMed ID: 8885146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass.
    Slight RD; Buell R; Nzewi OC; McClelland DB; Mankad PS
    J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):47-52. PubMed ID: 18249330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of high-dose heparin on inflammatory and coagulation parameters following cardiopulmonary bypass.
    Paparella D; Al Radi OO; Meng QH; Venner T; Teoh K; Young E
    Blood Coagul Fibrinolysis; 2005 Jul; 16(5):323-8. PubMed ID: 15970715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An investigation of a new activated clotting time "MAX-ACT" in patients undergoing extracorporeal circulation.
    Leyvi G; Shore-Lesserson L; Harrington D; Vela-Cantos F; Hossain S
    Anesth Analg; 2001 Mar; 92(3):578-83. PubMed ID: 11226081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.